Back to Search Start Over

argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

Source :
GlobeNewswire. December 20, 2023
Publication Year :
2023

Abstract

ADDRESS study did not meet primary or secondary endpoints Pemphigus deprioritized as efgartigimod indication Update on BALLAD study GO/NO GO decision Conference call scheduled for today, December 20, 2023, at [...]

Subjects

Subjects :
Pemphigus
Banking, finance and accounting industries
Business

Details

Language :
English
Database :
Gale General OneFile
Journal :
GlobeNewswire
Publication Type :
News
Accession number :
edsgcl.776758764

Tools

Authors Abstract Subjects Details